Fig 1: Concentration-dependent inhibition of CCR5 signaling by ISO and MVC and effects on C2C12 cell viability. (A,B) Concentration–response curves for inhibition of CCL11 (1 μM) signaling via receptor CCR5 in C2C12 cells by ISO and MVC. Receptor activation was measured using enzyme-linked immunoassay to detect production of cAMP. The cAMP concentration induced by treatment with 30 μM Forskolin (FSK) for 15 min was taken as the maximum cAMP concentration. (C,D) Dose-dependent effects of ISO and MVC on C2C12 cell viability measured by CCK-8 assay.
Fig 2: ISO protects C2C12 myotubes against CCL11-induced atrophy through activating CCR5. (A–D) MyHC immunostaining (magnification 10×; scale bar = 100 µm) and quantification of myotubes. CK = control group, CCL11 = CCL11 (1 μM) treatment group, ISO (0.05 μM) = ISO (0.05 μM) combined with CCL11 (1 μM) treatment group, ISO (0.5 μM) = ISO (0.5 μM) combined with CCL11 (1 μM) treatment group, ISO (5 μM) = ISO (5 μM) combined with CCL11 (1 μM) treatment group. (E–H) Western blot and quantification of CCR5, MAFbx and MuRF1. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Supplier Page from MedChemExpress for Eotaxin/CCL11 Protein, Mouse